Compare TransMedics Group Inc (TMDX) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Weibo Corp — how do they compare? TransMedics Group Inc trades at $78.15 (market cap $2.74B), while Weibo Corp trades at $6.55 (market cap $1.56B). The key difference: TransMedics Group Inc is the larger of the two by market cap, and Weibo Corp pays a 9.47% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold TransMedics Group Inc for 24 Days and Weibo Corp for 102 Days on average.
| TMDX | WB | |
|---|---|---|
Market Cap | $2.74B | $1.56B |
Volume | 949,331 | 812,503 |
Sector | Health | Media |
52-Week High | $150.42 | $12.37 |
52-Week Low | $61.99 | $6.33 |
Typical Hold Time | 24 Days | 102 Days |
Enterprise Value | $3.13B | $786.69M |
Dividend Yield | — | 9.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $78.17, down 3.58% on the day, with a bearish technical signal and mixed earnings history. The company reported strong 2025 results with $605.49M revenue and $190.29M net income, but 2026 projections show margin compression. Recent news highlights insider buying and leadership changes alongside legal investigations into fiduciary duties, creating a complex sentiment backdrop.
The stock offers growth potential with a consensus price target of $99.75, but faces risks from earnings misses, margin pressure, and ongoing legal scrutiny. Analyst consensus remains bullish with 69% buy ratings, yet investors must weigh robust profitability metrics against execution and regulatory uncertainties.
Weibo (WB) trades at $6.54, up 0.93% with bearish technical signals despite attractive valuation metrics including a P/E of 5.32 and P/B of 0.4. The company reported mixed Q2 2026 earnings with a beat on EPS but faces declining user metrics and advertising challenges. Net cash flow turned negative in 2024 at -$694M before recovering to $408M in 2025, while revenue has remained stagnant around $1.8B annually.
WB presents as a deep-value play with strong profitability margins but limited growth visibility. The stock's upside depends on advertising recovery and user engagement stabilization, though competitive pressures and China's regulatory environment pose significant risks. Analyst consensus is divided with 41% buy ratings, reflecting uncertainty about the company's ability to reignite growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
